Polypill Strategy for Heart Failure With Reduced Ejection Fraction
Public ClinicalTrials.gov record NCT04633005. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Polypill Strategy for the Evidence-Based Management of Heart Failure With Reduced Ejection Fraction in an Underserved Patient Population
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Heart failure with a reduced ejection fraction (HFrEF) represents a significant public health burden in the United States, with a growing prevalence particularly among African Americans and Hispanic Americans and individuals of low socioeconomic status (SES). Although effective therapies exist, gaps in their uptake contribute substantially to the excess burden of heart failure. The "polypill" is an inexpensive once daily pill containing three agents proven to improve morbidity and mortality in heart failure and represents potential strategy for increasing the utilization of proven HF therapies. The proposed study is a pragmatic, single-center, randomized trial to test the feasibility and effectiveness of a polypill-based strategy for the treatment of HFrEF in a low-income, racially diverse population.
Study identification
- NCT ID
- NCT04633005
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 212 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 14, 2021
- Primary completion
- Oct 14, 2025
- Completion
- Oct 30, 2025
- Last update posted
- Nov 20, 2025
2021 – 2025
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Texas Southwestern Medical Center | Dallas | Texas | 75209 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Heart Failure trials
Other public records listing Heart Failure. Sorted by last update posted; newest first. Not a recommendation.
- NCT07794930: Integrating Values Based Communication in Heart Failure Management Not yet recruiting
- NCT05585125: A Preliminary Study for INFORMED Recruiting
- NCT07232030: Barostim-Enabled NEurohormonal Intervention For Improving Treatment of Heart Failure Recruiting
- NCT07771231: Kosmos PLAX EF Pivotal Study Active, not recruiting
- NCT06812533: Alleviant ALLAY-HFrEF Study Recruiting
- NCT05685303: Alleviant ALLAY-HF Study Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04633005, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 20, 2025 · Synced Sep 9, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04633005 live on ClinicalTrials.gov.